IVD MEDICAL (01931) jumped more than 8% in early trading. As of press time, the stock was up 5.13% to HK$8.2 with turnover of HK$10.183 million.

On the news front, IVD MEDICAL recently issued an announcement stating that the board of directors believes purchasing and holding cryptocurrency is a crucial initiative for the group to strengthen its Ethereum (ETH) reserve treasury and accelerate the ecosystem development of the ivd.xyz exchange, among other business layouts and developments. It also represents an important component of the group's asset allocation strategy.

After careful consideration, the board proposes to seek prior shareholder approval to grant purchase authorization, empowering the board to conduct potential cryptocurrency purchases within a 36-month period from the date when the ordinary resolution regarding such purchase authorization and potential cryptocurrency acquisitions is formally passed at a special shareholders' meeting, with total purchases not exceeding HK$30 billion.

IVD MEDICAL's crypto asset strategy is not an isolated deployment but is deeply integrated with its core business - medical innovative drug asset tokenization (RWA). The company is leveraging its self-developed Web3 exchange ivd.xyz to transform high-value medical innovative drug assets into divisible tradeable digital certificates, building a "MicroStrategy (MSTR) + Summit Therapeutics (SMMT)" model in the medical RWA sector.

According to the announcement, Ethereum serves as the underlying infrastructure, not only providing value anchoring for RWA but also contributing to treasury scale through staking yields. The company disclosed that its "seven-layer downside protection mechanism" and "three-tier yield enhancement engine" have been fully activated, covering risk control measures including ATM financing, derivative hedging, RWA price buyback commitments, and others, ensuring shareholder interests are protected amid crypto market volatility.